|
Market Closed -
NSE India S.E.
15:05:06 25/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 5,368.00 INR | +0.34% |
|
-0.11% | -2.52% |
| 08-14 | Alkem Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026 | |
| 08-14 | Alkem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 432,909 | 406,055 | 590,890 | 583,680 | 633,575 | 641,825 | - | - |
| Change | - | -6.2% | 45.52% | -1.22% | 8.55% | 1.3% | - | - |
| Enterprise Value (EV) 1 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 628,745 | 613,767 | 604,964 |
| Change | - | -9.21% | 49.1% | -1.46% | 9.3% | -0.59% | -2.38% | -1.43% |
| P/E | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 28x | 24.3x | 21x |
| PBR | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 4.15x | 3.67x | 3.24x |
| PEG | - | -1x | 0.4x | 1.3x | 4.37x | -96.02x | 1.6x | 1.3x |
| Capitalization / Revenue | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 3.84x | 3.46x | 3.14x |
| EV / Revenue | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.77x | 3.3x | 2.96x |
| EV / EBITDA | 21.1x | 24.5x | 26.2x | 23x | 21x | 18.4x | 15.6x | 13.6x |
| EV / EBIT | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 21.2x | 17.9x | 15.5x |
| EV / FCF | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 61.1x | 30x | 23.7x |
| FCF Yield | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 1.64% | 3.33% | 4.22% |
| Dividend per Share 2 | 34 | 25 | 40 | 45 | 53 | 49.33 | 55.28 | 63.37 |
| Rate of return | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 0.92% | 1.03% | 1.18% |
| EPS 2 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 191.9 | 220.7 | 256 |
| Distribution rate | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 25.7% | 25% | 24.8% |
| Net sales 1 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 166,997 | 185,721 | 204,703 |
| EBITDA 1 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,213 | 39,286 | 44,365 |
| EBIT 1 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,727 | 34,232 | 39,074 |
| Net income 1 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,143 | 27,153 | 31,030 |
| Net Debt 1 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -13,079 | -28,058 | -36,861 |
| Reference price 2 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,299.00 | 5,368.00 | 5,368.00 | 5,368.00 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 13/05/22 | 19/05/23 | 29/05/24 | 29/05/25 | 28/05/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.87x | 3.75x | 18.31x | 0.92% | 6.68B | |
| 35.49x | 12.87x | 26.08x | 0.56% | 1,111B | |
| 30.37x | - | - | 1.97% | 658B | |
| 33.76x | 7.81x | 16.23x | 2.59% | 467B | |
| 20.64x | 4.89x | 12.12x | 2.7% | 369B | |
| 22.46x | 5.78x | 14.33x | 2.76% | 301B | |
| 21.25x | 4.36x | 12.44x | 2.02% | 256B | |
| 28.07x | 7.23x | 12.84x | 2.27% | 240B | |
| 13.6x | 4.83x | 10.09x | 3.78% | 207B | |
| -44.84x | 6.47x | 25.28x | 2.25% | 182B | |
| Average | 18.87x | 6.44x | 16.42x | 2.18% | 379.77B | |
| Weighted average by Cap. | 25.44x | 8.46x | 18.61x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
